Hey anything increased interest is a good thing.not sure how it ties together as investors are more likely to check financial sites for research. It's likely potential patients or families checking it out.
Great post Mann. The part that makes me believe that this is no joke is the partners they are conducting the studies with Sloan and Dana Farber just to name 2 very prominent hospitals, would not allow TROV to mislead the public at this point of the trials.
My window is between 10/15/15 - 1/15/16
Play those numbers "comeonmonday" and you will win.
Not enough after this week .i actually go to Pindars to pick up wine for the holidays. I'm not a big fan of the north fork reds but I do like the some of the whites. I mentioned Pindars because it seems to be the largest winery over there and I knew you would know it. I hear it's for sale so maybe I'll buy it in February after the BO.
So you think $ are now rotating into kerx. (Small cap) even though valuations concern still looms in the sector ?
It's pretty much what the industry avg is and we are pretty close to that % according to GM. So we are looking at about 325 scripts last week in total. .....?
But I will take the 300 scripts.........
Throwing up in my mouth daily but other than that , I'm good thank you.
We're gonna be ok with this one......eventually
He's a placeholder until January. Dont you think it's odd to make an announcement to hire 90 more reps and weeks later start a search for a VP of sales? When the knuckleheads in the field are only producing 200 scripts a week. How bout we just get the ones we have "to do their job"and stop complaining about co-pays etc.I just don't think he is calling those shots right now. They need those extra reps because they are going to be selling other drugs besides Auryxia come January and Kerx Is going to foot the bill to hire and train them.
I bet you a bottle of Pindar Select (fill in the blank) the VP of Sales comes from GS.